Mycophenolate mofetil (MMF) in combination with CsA seems to lead to earlier post transplant hematological recovery and less mucositis than MTX, with a similar incidence of GVHD. In this study we analyzed the post transplant outcomes of two cohorts of patients who underwent an HLA-identical sibling reduced intensity conditioning transplantation (allo-RIC) with GVHD prophylaxis consisting of CsA in combination with either MMF or a short course of MTX. We included 145 consecutive allo-RIC transplants performed between April 2000 and August 2007. The median follow-up for survivors was 41 months (4-105 months). The study group included 91 males. Median age was 55 years (range 18-71 years). Diagnoses included myeloid (n ¼ 65) and lymphoid (n ¼ 80) malignancies. GVHD prophylaxis consisted of CsA/MMF in 52 and CsA/MTX in 93 patients. The conditioning regimen was based on fludarabine in combination with BU (n ¼ 59) or melphalan (n ¼ 86). The occurrence of grade 2-4 mucositis was higher in the CsA/MTX group than in the CsA/MMF group (57 vs 23%, P ¼ 0.001). The cumulative incidence of acute and chronic GVHD was similar, 48 vs 50% and 71 vs 68%, respectively (P40.7). The 2-year relapse and OS were similar in the CsA/MTX and CsA/MMF groups (29 vs 21%, P ¼ 0.3 and 52 vs 51%, P ¼ 0.7, respectively). Our results support further prospective studies comparing the use of the CsA/MMF combination with CsA/MTX as GVHD prophylaxis in HLA-identical sibling donor allo-RIC recipients.
Introduction GVHD is the most concerning complication in allogeneic hematopoietic SCT (allo-HSCT). The introduction of reduced intensity conditioning (RIC) regimens has decreased the non-relapse mortality (NRM) in older and more complicated patients, 1 but allo-RICs do not seem to reduce the incidence and severity of GVHD, which is still the main cause of NRM. 2 To improve results after allo-HSCT, more effective GVHD prophylaxis is required. CsA in combination with a short course of MTX has been widely used since the late 1980s. 3, 4 However, MTX delays hematopoietic engraftment, worsens oral mucositis and may be associated with pulmonary and renal toxicity after allo-HSCT. [5] [6] [7] [8] In patients undergoing allo-RIC, reducing procedure-related toxicities may be of great importance, as these patients usually have greater comorbidities. Thus, in an attempt to reduce any MTX-associated toxicities, mycophenolate mofetil (MMF) has replaced MTX in RIC regimens in recent years. 9 MMF is an inhibitor of purine nucleotide de novo synthesis that impairs proliferation of activated lymphocytes. In combination with CsA, it has shown a good safety profile in phase II trials. 5, 10, 11 However, no differences in the rate of acute GVHD (aGVHD) were obtained after conventional high-dose allo-HSCT compared with standard CsA/MTX prophylaxis. 10, 11 A recent study by Neumann et al. 5 showed that CsA/MMF was as efficient as CsA/MTX for GVHD prophylaxis, but with faster hematopoietic recovery.
In view of these concerns, we report a retrospective study addressed to compare the combination of CsA/MMF and CsA/MTX in a large, homogenous patient population who received a PBSC HLA-identical sibling allo-RIC.
Patients and methods

Patients
We included 145 consecutive patients who were transplanted between 2000 and 2007 at two transplantation centers in Barcelona (Spain) using the same eligibility criteria, 52 patients from the Hospital Clinic of Barcelona (28 of them on CsA/MMF GVHD prophylaxis) and 93 from the Hospital de la Santa Creu i Sant Pau of Barcelona (24 of them on CsA/MMF GVHD prophylaxis). The indications for an allo-RIC included age over 50 years (n ¼ 105), the presence of severe comorbidities (n ¼ 18) or having undergone earlier SCT (n ¼ 22). All patients were included in a series of consecutive allo-RIC trials designed for patients who were not eligible for a conventional highdose myeloablative conditioning, as reported elsewhere in detail. 12, 13 All patients received an HLA-identical sibling allo-RIC and PBSC as the stem cell source without in vivo/ ex vivo T-cell depletion. All participants gave written informed consent, and the studies were approved by the national and local ethics committees.
Conditioning and GVHD prophylaxis
The conditioning regimens used have been described elsewhere. 12, 13 Briefly, fludarabine 150 mg/m 2 was combined with BU 8-10 mg/kg for myeloid malignancies (8 mg/kg for patients 465 years old; there were five patients in the CsA/MTX group and four in the CsA/ MMF group) or melphalan 70-140 mg/m 2 (for multiple myeloma and lymphoid malignancies, respectively).
GVHD prophylaxis consisted of CsA (0.5 mg/kg/twice daily) from day À7 in all patients. The dose was adjusted to blood levels (between 200 and 300 mg/ml). From 2000 to 2003, MTX was administered on days þ 1, þ 3 and þ 6 (10 mg/m 2 ), and folinic acid rescue was administered 24 h after MTX. Since 2004, MTX was substituted for MMF in an effort of reducing MTX toxicity. MMF was started on day 0 (at least 10 h after the infusion of progenitors) at a dose of 1 g three times daily (15 mg/kg/8 h). MMF was continued until day þ 30 and then tapered if no complete donor T-cell chimerism was achieved or no GVHD was observed. If GVHD was present at day þ 30, the tapering dose was delayed until recovery.
All patients received oral antimicrobial prophylaxis during neutropenia, which consisted of aciclovir 800 mg/ 12 h, levofloxacin 500 mg/day or ciprofloxacin 500 mg/12 h and fluconazol 200-400 mg/day. GVHD assessment and hematologic recovery Diagnosis of aGVHD was mainly based on the classical clinical presentation with confirmatory pathological findings in all patients. aGVHD and chronic GVHD (cGVHD) were assessed and graded according to published criteria. 14 We included late-onset aGVHD (after day þ 100), based on clinical manifestations and biopsies. It is currently recognized that aGVHD may occur several weeks after day þ 100, especially when mixed T-cell chimerism lasts more than 100 days after allo-HSCT. 15 All patients who survived at least 15 days were evaluated for hematopoietic recovery. Neutrophil and plt engraftment was defined as the first of three consecutive days with an ANC of 40.5 Â 10 9 /l and an untransfused plt count of 420 Â 10 9 /l. G-CSF was not used in any patient.
Mucosal toxicity assessment
We retrospectively included the oral mucositis data, on the basis of prospective daily evaluation reported in the patient's charts. While admitted in the hospital, patients were evaluated on daily basis for mucositis by a trained nurse and a physician. Mucosal toxicity was graded according to the WHO criteria (grade 1, painless ulcers, erythema or soreness; grade 2, painful erythema, edema or ulcers, the patient can eat; grade 3, painful erythema, edema or ulcers, the patient cannot eat but can drink and grade 4, the patient cannot eat or drink and enteral or parenteral nutrition is necessary). The final recorded score of mucositis for an individual patient was defined as the maximum WHO score, recorded during the neutropenia after conditioning.
Chimerism analyses
Chimerism was evaluated at day 28 after transplant in peripheral blood in most patients (n ¼ 128). Chimerism analysis was performed by using a PCR for informative minisatellite loci, as previously specified. 16 T cells complete donor chimerism (CDC) was defined as the presence of at least 95% donor DNA in the sample analyzed.
Risk assessment
At transplantation, advanced disease status was considered in patients with AML or ALL in X2nd CR, myeloproliferative disease in X2nd CR and in accelerated or blast phase, Hodgkin's disease in X3rd remission or with PR, follicular lymphoma X3rd CR, and large B-cell lymphoma or multiple myeloma 42nd CR or PR. Patients with PR or persistent disease at transplantation (except for MM) were also considered as advanced disease status.
Statistical data
The primary end points were to compare the incidence of gastrointestinal toxicity and the time to hematopoietic recovery. Secondary end points were the incidence of aGVHD and cGVHD, relapse rate, NRM and OS. Neutrophil recovery, plt recovery, aGVHD and cGVHD and NRM were calculated using the cumulative incidence model, with relapse as the competitive variable. 17 Median time to hematopoietic recovery, median time of onset of GVHD and median time to CDC were compared using the Wilcoxon rank-sum test. Risk factors for aGVHD and NRM were estimated using the univariate Cox regression model. 18 Variables with a P-value below 0.1 were included in multivariate analysis. OS was assessed by the Kaplan-Meier method and compared using the Taronware and the log-rank test. 19 Tests of significance were two-sided, with significance set at a P-level of 0.05 or less. All statistical analyses were performed using SPSS version 15.0 (SPSS, Chicago, IL, USA), with the exception of the cumulative incidence analyses, which were carried out with NCSS 2006 (Number Cruncher Statistical System, Kaysville, UT, USA). If GVHD prophylaxis, aGVHD or other variables were found to have an impact on post transplantation outcomes in the final multivariate Cox analysis, plots were constructed to visually illustrate the effects of each variable on these outcomes, as described elsewhere. 20 CsA/MMF vs CsA/MTX as GVHD prophylaxis in allo-RIC JL Piñana et al
Results
Patient characteristics
From January 2000 to August 2007, 145 consecutive HLAidentical sibling donor PBSC allo-RIC patients were included in this study. Their characteristics are summarized in Table 1 . We first compared the patient characteristics and outcomes in each transplant center and we did not found differences (data not shown). There were 93 patients who received CsA and MTX as GVHD prophylaxis (CsA/MTX group) and 52 patients received CsA and MMF (CsA/ MMF group). Although we restricted our analysis to patients with HLA-identical sibling donors and peripheral blood as stem cell source, there were still significant differences between the two GVHD prophylaxis cohorts reflecting the retrospective character of the study. Patients in the CsA/MTX group had more often received an earlier autologous transplant (67 vs 50%, P ¼ 0.01), had received more than two earlier lines of chemotherapy before transplantation (44 vs 27%, P ¼ 0.05) and had a trend for a higher rate of advanced disease (41 vs 22%, P ¼ 0.06). Therefore, we paid particular attention to these factors during the analysis. Other patient characteristics did not differ between both study cohorts. As expected, the median follow-up was longer in the CsA/MTX group. . Three (4%) of 70 patients diagnosed of GVHD developed grade 4 aGVHD, 10 (14%) of 70 had grade 3, 37 (53%) of 70 patients had grade 2 and 20 (29%) of 70 developed grade 1. Seven (10%) of 70 patients developed aGVHD after day þ 100 (three in the CsA/MTX group and four in the CsA/MMF group) and were classified as late-onset aGVHD. The skin was the main organ affected in 53 (76%) of the 70 cases of aGVHD (32 (72%) of 44 patients with aGVHD in the CsA/MTX group and 21 (81%) of 26 cases of aGVHD in the CsA/ MMF group), while gastrointestinal involvement was reported in 36 (51%) of 70 cases (21 (48%) of the 44 patients in the CsA/MTX group and 15 (58%) of the 26 in the CsA/MMF group), and liver in 15 cases (13 (30%) of 44 in the CsA/MTX vs 2 (8%) of 26 in the CsA/MMF group, P ¼ 0.04). Steroid-refractory aGVHD occurred in 21 (30%) of 70 patients (CsA/MTX n ¼ 14 (32%) and CsA/MMF n ¼ 7 (27%)). All three (100%) patients with grade 4, 7 (70%) of 10 patients with grade III and 11 (41%) of 37 with grade II had steroid-refractory aGVHD. We found no statistically significant differences between the two groups of patients in the incidence of grade 2-4 ( Table 1) . cGVHD was observed in 78 (76%) of 102 evaluable patients. Extensive cGVHD occurred in 42 (61%) of 78 patients (26 (41%) of 64 evaluable patients in the CsA/ MTX group and 16 (42%) of 38 evaluable patients in the CsA/MMF group). The cumulative incidence of cGVHD and extensive cGVHD did not differ between the two study cohorts ( Table 1) .
The day þ 28 granulocyte and lymphocyte chimerism analysis was available in 128 and 100 patients, respectively. The incidence of early T-cell CDC was somewhat higher in the CsA/MTX group, but the differences were not statistically significant (63 vs 44%, P ¼ 0.2) ( Table 1) . However, we observed a significantly earlier median onset of cGVHD in the CsA/MTX group and a trend for earlier onset of aGVHD was also observed (Table 1) .
NRM
Forty-five (31%) of 145 patients died because of NRM after a median follow-up of 514 days (range 8-3170). Median time to death was 113 days (range 8-1072). The day þ 100 and 2-year cumulative incidence of NRM for the whole group was 13% (95% confidence interval: 9-20) and 27% (95% confidence interval: 21-35), respectively. Thirteen (25%) of 52 patients died in the CsA/MMF group and 32 (34%) of 93 in the CsA/MTX. The causes of death according to the GVHD prophylaxis are shown in Table 2 . As a relevant finding, patients in the CsA/MTX group died more often of non-aGVHD etiology in the early period (9/93, 10%) compared with those receiving CsA/MMF (1/52, 2%). The cumulative incidences of early and late NRM according to GVHD prophylaxis are shown in Table 3 .
The multivariate analysis of NRM is shown in Table 3 . Variables associated with day þ 100 NRM were as follows: CsA/MTX-based GVHD prophylaxis (hazard ratio (HR) 3.1 (P ¼ 0.07)), advanced disease status (HR 5.1 (P ¼ 0.03)) and ECOG41 (HR 3.5 (P ¼ 0.006)). The factors associated with higher 2-year NRM were as follows: prior autologous transplant (HR 3.1 (P ¼ 0.05)), ECOG 41 (HR 2.6 (P ¼ 0.003)) and lymphoid malignancy (HR 2.4 (P ¼ 0.01)). Representative curve of the impact of GVHD prophylaxis regimen on NRM is shown in Figure 1 .
Relapse and OS
Relapse at 2 years occurred in 29% of patients receiving CsA/MMF prophylaxis compared with 21% in the CsA/ MTX group (P ¼ 0.3) ( Table 1) . Two-year OS was also similar in both groups (Figure 2 ).
Discussion
In line with several studies comparing the introduction of MMF instead of MTX as GVHD prophylaxis in Table 2 Cause of death according to the GVHD prophylaxis allo-HSCT, 5, 10, 21 in this retrospective study we report a similar incidence of GVHD and possibly a somewhat improved toxicity profile in favor of the CsA/MMF combination. It is important to note, however, that earlier studies comparing the impact of such combinations on the toxicity profile, the incidence of GVHD and transplantrelated mortality, had considerable limitations. These studies had substantial differences between groups in terms of conditioning regimens (TBI and non-TBI regimens), donor types (related and unrelated donors), stem cell sources (PBSC and BM) and the dose of MMF used. In an effort to reduce such limitations, we focused our study on similar allo-RIC regimens, PBSC as the source of stem cells and HLA-identical sibling donors only, and all patients received the same dose (3 g/daily) of MMF.
As reported by Kiehl et al. 21 and Bolwell et al, 10 we found a lower rate of severe mucositis in patients who received CsA/MMF GVHD prophylaxis. Especially, relevant is the absence of grade 4 oral mucositis in this group. However, we did not find any statistically significant differences in hematopoietic recovery. Neumann et al. 5 and Bolwell et al. 10 found a faster neutrophil recovery with CsA/MMF than with CsA/MTX in myeloablative allo-HSCT. The difference between these findings and ours could be partly explained by the different dosage of MMF used: these authors used 2 g/day MMF in many patients, whereas we used 3 g/day in all our patients. As MMF may have hematopoietic toxicity, 22, 23 it is conceivable that a higher dose may account for delayed hematopoietic recovery. Nonetheless, we believe that the most likely explanations include the high-dose myeloablative conditioning regimens used in these studies, as well as the predominance of BM as the stem cell source, as opposed to the allo-RIC regimens and PBSC used in our patients, as these variables lead to faster hematopoietic recovery. [24] [25] [26] Thus, it may be very difficult in the allo-RIC PBSCT setting to find differences in hematopoietic recovery.
The homogeneous dosage of MMF used in all of our CsA/MMF patients makes comparison between these two combinations more reliable in terms of incidence of GVHD. We selected higher doses of MMF in view of several publications that showed that MMF had lower mycophenolic acid concentration levels when combined with CsA. 11, 27 Recent findings from animal model studies have also supported the suggestion that mycophenolic acid levels were lower in allo-HSCT than in solid-organ transplantation. 28 Furthermore, pharmacokinetic assays of mycophenolic acid have shown a higher therapeutic area under the curve at a dosage of 3 g daily in unrelated donor allo-RIC. 29, 30 An interesting observation in our study was that patients who received CsA/MTX had an earlier median onset of cGVHD (146 days) than those in the CsA/MMF group (186 days). This may reflect a longer immunosuppression exposure in the CsA/MMF group. Another observation was the higher degree of T-cell CDC at day þ 28 in the former group, although not reaching statistical significance.
The suggestion that MMF may delay T-cell CDC is partly supported by the observation in an animal model that MMF prolongs mixed hematopoietic chimerism after nonmyeloablative HSCT. 31 Although the development of RIC regimens has allowed patients who are ineligible for standard allo-HSCT to benefit from allogeneic therapy, NRM remains a significant obstacle to its success. While the association between low performance status (ECOG 41) and advanced disease status with early NRM has been previously reported by us and other groups in allo-RIC regimens, 8, 24, 32, 33 this is the first observation, to the best of our knowledge, that CsA/ MTX GVHD prophylactic regimen showed a relevant trend to a higher early NRM for patients who underwent HLA-identical sibling peripheral blood allo-RIC. Nonetheless, it is well know that MTX has several potentially relevant toxicities (pulmonary, hepatic, gastrointestinal and hematopoietic toxicity). 6, 7 In addition, we recently reported that MTX is a risk factor for early acute renal failure, which may contribute to early and late NRM in allo-RIC patients. 8 The higher rate of mucositis, the trend to higher rate of neutropenic fever in addition to a more frequent early non-related GVHD deaths, observed in this group of patients, may support the higher toxicity of MTX. These potential organ toxicities may contribute to increasing the early NRM in this debilitated group of patients.
Nevertheless, although we included earlier autologous HSCT, number of earlier chemotherapy lines before allo-RIC and advanced disease status in the multivariate modeling, we cannot rule out completely the possibility that these factors could contribute to the higher NRM in the CsA/MTX group, especially earlier autologous HSCT that was more frequent in the CsA/MTX group and which was related in multivariate analysis with higher late NRM.
Concerning late NRM, the effect of CsA/MTX and advanced disease status disappeared, while ECOG 41 persisted as risk factor throughout the transplant. In line with earlier reports, earlier autologous HSCT had a deleterious effect in the outcome of allo-RIC. 32 In addition, lymphoid malignancies appear to have a poorer outcome. Historically, lymphoid malignancies have had poor results after allo-HSCT. 34, 35 Patients with lymphoid malignancies have generally been transplanted in more advanced disease status and have received a greater number of therapy lines than those with myeloid disease. 34, 36 Allo-HSCT in this setting is thus a greater challenge for physicians and investigators.
In conclusion, our study supports the use of MMF plus CsA as GVHD prophylaxis in allo-RIC adult patients. However, larger studies are warranted to elucidate whether MMF in combination with CsA provides any benefit over the classical combination of CsA/MTX in terms of hematopoietic recovery, GVHD, NRM and OS.
